WO2024214088 - HETEROCYCLIC COMPOUNDS AS DUAL INHIBITORS OF PD-L1 AND ADENOSINE RECEPTORS
National phase entry:
Publication Number
WO/2024/214088
Publication Date
17.10.2024
International Application No.
PCT/IB2024/053673
International Filing Date
15.04.2024
Title **
[English]
HETEROCYCLIC COMPOUNDS AS DUAL INHIBITORS OF PD-L1 AND ADENOSINE RECEPTORS
[French]
COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DOUBLES DE PD-L1 ET DE RÉCEPTEURS D'ADÉNOSINE
Applicants **
AURIGENE ONCOLOGY LIMITED
Inventors
VENKATESHAPPA, Chandregowda
SAMAJDAR, Susanta
PUTTA, V P Rama Kishore
Priority Data
202321027615
14.04.2023
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3895 | |
| EPO | Filing, Examination, Granting | 27829 | |
| Japan | Filing, Examination, Granting | 3148 | |
| South Korea | Filing, Examination, Granting | 3879 | |
| USA | Filing, Examination, Granting | 12640 |
Total:
51,391
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present application relates to heterocyclic compounds represented by compound of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof which are useful as dual inhibitors of PD-L1 and Adenosine receptors (A2AR). The present application also relates to pharmaceutical compositions comprising said compounds or a pharmaceutically acceptable salt or a stereoisomer thereof and use of such compounds in the treatment of diseases mediated by PD-L1 and A2AR.[French]
La présente demande concerne des composés hétérocycliques représentés par le composé de formule (I), un sel pharmaceutiquement acceptable ou un stéréoisomère de celui-ci qui sont utiles en tant qu'inhibiteurs doubles de PD-L1 et de récepteurs d'adénosine (A2AR). La présente demande concerne également des compositions pharmaceutiques comprenant lesdits composés, un sel pharmaceutiquement acceptable ou un stéréoisomère de ceux-ci et l'utilisation de tels composés dans le traitement de maladies médiées par PD-L1 et A2AR.